CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,786,653 | +62.2% | 64,922 | +100.0% | 0.00% | +100.0% |
| Q2 2023 | $1,101,402 | -33.1% | 32,461 | -29.1% | 0.00% | -50.0% |
| Q1 2023 | $1,646,481 | -33.2% | 45,761 | -17.2% | 0.00% | -33.3% |
| Q4 2022 | $2,462,983 | +82.3% | 55,261 | +15.9% | 0.00% | +50.0% |
| Q3 2022 | $1,351,000 | +36.7% | 47,661 | +30.0% | 0.00% | +100.0% |
| Q2 2022 | $988,000 | -60.7% | 36,661 | -50.3% | 0.00% | -50.0% |
| Q1 2022 | $2,515,000 | +4.4% | 73,829 | +18.5% | 0.00% | 0.0% |
| Q4 2021 | $2,408,000 | -28.4% | 62,329 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $3,365,000 | +71.2% | 62,329 | +38.7% | 0.00% | +50.0% |
| Q2 2021 | $1,966,000 | +317.4% | 44,929 | +96.6% | 0.00% | +100.0% |
| Q1 2021 | $471,000 | +64.1% | 22,850 | +39.3% | 0.00% | – |
| Q4 2020 | $287,000 | – | 16,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |